Literature DB >> 6370907

The diagnosis of thymoma in myasthenia gravis.

J A Aarli.   

Abstract

Between 10 and 15 per cent of patients with myasthenia gravis (MG) have a thymoma. We have evaluated the possibility of detecting such tumours on the basis of clinical features, radiological findings and immunological tests in a group of 70 MG patients. The mean age at onset of myasthenic symptoms was 67.6 years in the thymoma group and 33.8 years in the non-thymoma group. Otherwise, the clinical picture was similar. Radiological examination revealed a mediastinal mass in 2 patients. Six of the 70 MG sera contained antibodies to a citric acid (CA) extract of striated muscle. At thymectomy, a thymoma was found in these 6 patients. None of the remaining 64 patients had evidence of a thymoma. Antibodies to AChR were detected in 52 of the 70 MG sera. There was no relation between titres of AChR and CA antibodies. Three out of 5 sera from non-MG patients with a thymoma contained CA antibodies. Apparently, this assay is a valuable technique for the identification of a thymoma at an early stage.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6370907     DOI: 10.1007/bf02125617

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  16 in total

1.  TANNED-CELL HEMAGGLUTINATION TEST FOR DETECTION OF ANTIBODIES IN SERA OF PATIENTS WITH MYASTHENIA GRAVIS.

Authors:  A Y DJANIAN; E H BEUTNER; E WITEBSKY
Journal:  J Lab Clin Med       Date:  1964-01

2.  Muscle and thymus antibodies in myasthenia gravis.

Authors:  H J OOSTERHUIS
Journal:  Vox Sang       Date:  1963 Mar-Apr       Impact factor: 2.144

3.  MYASTHENIA GRAVIS AND TUMORS OF THE THYMIC REGION: REPORT OF A CASE IN WHICH THE TUMOR WAS REMOVED.

Authors:  A Blalock; M F Mason; H J Morgan; S S Riven
Journal:  Ann Surg       Date:  1939-10       Impact factor: 12.969

4.  The reactivity of the antistriational antibodies associated with thymoma and myasthenia gravis.

Authors:  J Peers; B L McDonald; R L Dawkins
Journal:  Clin Exp Immunol       Date:  1977-01       Impact factor: 4.330

5.  Precipitation of autoantibody in serum from patients with myasthenia gravis.

Authors:  S Shulman; R Lang; E Beutner; E Witebsky
Journal:  Immunology       Date:  1966-04       Impact factor: 7.397

6.  Antiglobulin consumption test with sera from patients with myasthenia gravis.

Authors:  J A Aarli; O Tönder
Journal:  Clin Exp Immunol       Date:  1970-07       Impact factor: 4.330

7.  Thymoma-specific antibodies in sera from patients with myasthenia gravis demonstrated by indirect haemagglutination.

Authors:  J A Aarli; A K Lefvert; O Tönder
Journal:  J Neuroimmunol       Date:  1981-12       Impact factor: 3.478

8.  Serological detection of thymoma in myasthenia gravis.

Authors:  J A Aarli; S Thunold
Journal:  Eur Neurol       Date:  1981       Impact factor: 1.710

9.  Myasthenia gravis. Antibodies to an acid-soluble antigen in striated muscle.

Authors:  J A Aarli
Journal:  Clin Exp Immunol       Date:  1972-03       Impact factor: 4.330

10.  Thymomas.

Authors:  D P LeGolvan; M R Abell
Journal:  Cancer       Date:  1977-05       Impact factor: 6.860

View more
  1 in total

1.  Epstein-Barr virus genome in thymoma and thymic lymphoid hyperplasia.

Authors:  L J McGuire; D P Huang; R Teoh; M Arnold; K Wong; J C Lee
Journal:  Am J Pathol       Date:  1988-06       Impact factor: 4.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.